Personalis to Participate at Upcoming Investor Conferences
Personalis (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, has announced its participation in two upcoming investor conferences. The company will join the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, featuring a fireside chat at 12:30 PM ET at The Lotte New York Palace. Additionally, Personalis will participate in TD Cowen's Diagnosing Tomorrow: Tools & Technologies for the Next Decade conference on December 12, 2024, contributing to a panel discussion on 'MRD - The Future Tech Stack' at 1:30 PM ET at One Vanderbilt in New York.
Personalis (Nasdaq: PSNL), leader nella genomica avanzata per l'oncologia di precisione, ha annunciato la sua partecipazione a due prossimi conferenze per investitori. L'azienda parteciperà al 36° Convegno Annuale sulla Sanità di Piper Sandler il 3 dicembre 2024, con un incontro informale alle 12:30 PM ET presso il Lotte New York Palace. Inoltre, Personalis prenderà parte alla conferenza Diagnosing Tomorrow: Strumenti e Tecnologie per il Prossimo Decennio di TD Cowen il 12 dicembre 2024, contribuendo a una discussione di panel su 'MRD - Il Futuro della Tech Stack' alle 1:30 PM ET presso One Vanderbilt a New York.
Personalis (Nasdaq: PSNL), líder en genómica avanzada para oncología de precisión, ha anunciado su participación en dos próximas conferencias para inversores. La compañía se unirá a la 36ª Conferencia Anual de Atención Médica de Piper Sandler el 3 de diciembre de 2024, participando en una charla informal a las 12:30 PM ET en el Lotte New York Palace. Además, Personalis participará en la conferencia Diagnosing Tomorrow: Herramientas y Tecnologías para la Próxima Década de TD Cowen el 12 de diciembre de 2024, contribuyendo en una discusión de panel sobre 'MRD - El Futuro del Stack Tecnológico' a la 1:30 PM ET en One Vanderbilt en Nueva York.
Personalis (Nasdaq: PSNL)는 정밀 암 치료를 위한 고급 유전체학의 선두주자로서 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. 이 회사는 2024년 12월 3일에 개최되는 파이퍼 샌들러 제36회 연례 의료 회의에 참석하며, 오후 12:30 ET에 뉴욕의 Lotte New York Palace에서 화로 앞 토론에 참여할 예정입니다. 또한, Personalis는 2024년 12월 12일에 개최되는 TD Cowen의 내일 진단: 향후 10년을 위한 도구 및 기술 회의에 참여하여 오후 1:30 ET에 뉴욕의 One Vanderbilt에서 'MRD - 미래 기술 스택'에 대한 패널 토론에 기여할 것입니다.
Personalis (Nasdaq: PSNL), leader en génomique avancée pour l'oncologie de précision, a annoncé sa participation à deux prochaines conférences pour investisseurs. La société participera à la 36e Conférence Annuelle sur les Soins de Santé de Piper Sandler le 3 décembre 2024, avec une discussion au coin du feu à 12h30 ET au Lotte New York Palace. De plus, Personalis prendra part à la conférence TD Cowen's Diagnosing Tomorrow: Outils et Technologies pour la Prochaine Décennie le 12 décembre 2024, contribuant à une discussion de panel sur 'MRD - La Future Tech Stack' à 13h30 ET à One Vanderbilt à New York.
Personalis (Nasdaq: PSNL), führend in fortschrittlicher Genomik für präzise Onkologie, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird am 3. Dezember 2024 an der 36. jährlichen Healthcare-Konferenz von Piper Sandler teilnehmen und um 12:30 Uhr ET bei einem informellen Gespräch im Lotte New York Palace zugegen sein. Darüber hinaus wird Personalis an der Konferenz TD Cowens Diagnosing Tomorrow: Werkzeuge und Technologien für das nächste Jahrzehnt am 12. Dezember 2024 teilnehmen und zu einer Podiumsdiskussion über 'MRD - Der zukünftige Tech-Stack' um 13:30 Uhr ET in One Vanderbilt in New York beitragen.
- None.
- None.
-
Piper Sandler 36th Annual Healthcare Conference
Date: Tuesday, December 3, 2024
Fireside Chat Time: 12:30 pm Eastern Time
Location: The Lotte New York Palace inNew York, NY
-
TD Cowen Diagnosing Tomorrow: Tools & Technologies for the Next Decade
Date: Thursday, December 12, 2024
Panel Topic: MRD - The Future Tech Stack
Panel Time: 1:30 pm Eastern Time
Location: One Vanderbilt inNew York, NY
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241120667294/en/
Investors:
Caroline Corner
investors@personalis.com
415-202-5678
Media:
pr@personalis.com
Source: Personalis, Inc.
FAQ
When is Personalis (PSNL) presenting at the Piper Sandler Healthcare Conference in 2024?
What panel is Personalis (PSNL) participating in at the TD Cowen conference?
Which investor conferences will Personalis (PSNL) attend in December 2024?
